https://www.bloomberg.com/news/arti...its-fda-panel-as-furor-over-biogen-drug-grows
The third committee member to quit after the Biogen approval.
The problem has to do with approving the drug on too little solid evidence. Hopefully it will cause the FDA to rethink the soft approach to prematurely approving treatments that really haven't achieved success in properly conducted confirmatory RCTs.
https://www.bloomberg.com/news/articles/2021-06-10/harvard-expert...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |